Merit Medical Systems (NASDAQ:MMSI) Issues FY 2025 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 3.280-3.410 for the period, compared to the consensus EPS estimate of 3.350. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Merit Medical Systems Trading Down 0.6%

Shares of Merit Medical Systems stock opened at $92.97 on Friday. Merit Medical Systems has a 12-month low of $80.02 and a 12-month high of $111.45. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 45.57, a PEG ratio of 2.34 and a beta of 0.66. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The company’s 50-day moving average price is $94.51 and its 200-day moving average price is $99.59.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.11. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The firm had revenue of $355.35 million for the quarter, compared to the consensus estimate of $352.57 million. During the same period in the prior year, the firm posted $0.77 earnings per share. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, equities analysts expect that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MMSI has been the topic of several research analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Merit Medical Systems in a research report on Friday, March 28th. They issued an “overweight” rating and a $120.00 price objective on the stock. Robert W. Baird decreased their price objective on shares of Merit Medical Systems from $111.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Barrington Research decreased their price objective on shares of Merit Medical Systems from $111.00 to $103.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Needham & Company LLC upped their price objective on shares of Merit Medical Systems from $100.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th. Finally, Piper Sandler restated an “overweight” rating and issued a $110.00 price objective (up from $106.00) on shares of Merit Medical Systems in a research report on Friday, May 23rd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $109.11.

Insider Buying and Selling at Merit Medical Systems

In other news, Director F. Ann Millner sold 21,250 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $96.47, for a total value of $2,049,987.50. Following the transaction, the director now owns 34,543 shares in the company, valued at approximately $3,332,363.21. This trade represents a 38.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Fred P. Lampropoulos sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $96.54, for a total transaction of $1,930,800.00. Following the completion of the transaction, the chief executive officer now owns 1,066,028 shares in the company, valued at $102,914,343.12. This represents a 1.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 70,415 shares of company stock worth $6,748,214 over the last ninety days. Insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Merit Medical Systems stock. AQR Capital Management LLC lifted its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 7.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,361 shares of the medical instruments supplier’s stock after purchasing an additional 1,114 shares during the period. AQR Capital Management LLC’s holdings in Merit Medical Systems were worth $1,730,000 as of its most recent SEC filing. Institutional investors and hedge funds own 99.66% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.